The clinical course in 50 (Br3 Ophthalmol 1994; 78: 433-436) 
In all cases included into this study progression ofnew vessels occurred. Consequently these eyes were assigned to pars plana vitrectomy.
Apart from progression of neovascularisations and despite extensive laser photocoagulation treatment and peripheral cryotherapy, further entry criteria had to be fulfilled: eyes were eligible for entry if flat fibrovascular tissue covering the macula had led to visual impairment without significant detachment of the macula. Also absence of posterior vitreous detachment, traction retinal detachment, and vitreous haemorrhage were mandatory. Decrease in visual acuity was not due to tractional detachment of the macula but was caused by the fibrovascular tissue. This may be explained by the opacity of the proliferative membranes and/ or impairment of the blood-retina barrier in the macular area. All in our patient group. Moreover, no signs of partial retinal or vitreous detachment were present. Because of these special entry criteria our results are only partially comparable with previous studies.
Intraoperative bleeding occurred in some of our cases, especially when the posterior hyaloid together with the vasoproliferative tissue were removed from the optic disc. In contrast with our experience with the membrane dissection technique, which we have used in former times, the en bloc resection technique reduces the incidence of intraoperative bleeding. Thus, endodiathermy had to be used in 26% of the operations only. This may be due to the fact that en bloc resection amputates the new vessels at the site of their origin where the new vessels have muscle cells comparable with the retinal vasculature. This may also explain the observation that bleeding from larger trunks often stops sooner than haemorrhages from smaller extensions of the neovascular network. '3 Despite the fact that in our study only two eyes redeveloped new retinal vessels on the retinal surface during follow up, in 15 eyes temporary bleeding in the vitreous cavity occurred. Postoperative haemorrhages occurred predominantly in the first 6 months after vitrectomy and resolved spontaneously in most cases. A lavage procedure had to be performed in only five eyes. One of these cases needed a relavage procedure 8 months later. Focal endolaser photocoagulation became avoidable after switching from the membrane dissection technique to the en bloc resection technique. Therefore, no focal endophotocoagulation of severed epicentres was necessary.
Rebleeding into the vitreous cavity occurred in 15 eyes; in one case a relavage became necessary. Haemorrhages are a frequent complication after vitrectomy in diabetics.'415 Any bleeding during the early postoperative course tends to clear rapidly, although the rate of clearing depends on the amount ofhaemorrhage. A major therapeutic problem is the recurrence of vitreous haemorrhage which is a clinical feature of anterior hyaloidal fibrovascular proliferations (AHFP). 16 Lewis et al used panretinal argon laser endophotocoagulation in all patients with recurrent haemorrhages due to AHFP except those who already had extensive panretinal photocoagulation before surgery.'718 Because all eyes included in our study had been treated with extensive panretinal photocoagulation and peripheral cryotherapy preoperatively no further intraoperative photocoagulation was performed.
Four of five eyes with preoperative rubeosis iridis showed regression after pars plana vitrectomy. Other investigations revealed an increase of iris neovascularisations after vitrectomy, especially in cases with combined lensectomy. [19] [20] [21] Interestingly, postoperative rubeosis iridis developed in only 2% of eyes with an uncomplicated postoperative course.22 Eyes with mild or moderate rubeosis iridis were also eligible for entry in the prospective diabetic retinopathy vitrectomy study."' But neither any correlation with the visual outcome nor progression of rubeosis iridis postoperatively are reported. The regression of mild rubeosis iridis in four of five eyes could be independent of the vitrectomy but could also be related to the extensive panretinal laser photocoagulation applied preoperatively. In a prospective study by Doft and Blankenship 36% of eyes that failed to show an initial favourable response by 3 weeks, did show a delayed improvement in low risk characteristics at 6 months. 23 The anatomical alteration at the vitreoretinal interface performed by pars plana vitrectomy is comparable with a complete posterior vitreous detachment. Akiba et al reported an incidence of neovascularisations in diabetic retinopathy of only 3% in eyes with complete posterior detachment. 24 This low incidence of retinal neovascularisation is comparable with the rate of proliferations after diabetic vitrectomy. Rice and Michels also report a reproliferation rate of 3% after vitrectomy for diabetic retinopathy.2' Fibrovascular proliferation seems to be reduced when the scaffold of the adjacent posterior vitreous surface is absent. 25 Only two of our patients (4%) showed neovascularisations at the posterior pole during follow up. The reason for reproliferations inAhese two cases is speculative because the en bloc resection during vitrectomy has been extended to the extreme periphery using scleral indentation. This operative technique leaves no vascular epicentre islands.
In this study visual acuity improved in 72% of the eyes, worsened in 10%, and was unchanged in 18%. Reasons for deterioration ofvisual acuity were atrophy of the optic nerve (one), acceleration of exudative maculopathy (two), macular oedema (one), and rebleeding (one). All these findings can not only be attributed to the surgical procedure but could also occur without vitrectomy.
Our results suggest that pars plana vitrectomy can preserve an economically or at least socially useful visual acuity6 in 90% of the eyes which fulfil the above mentioned eligibility criteria. We do not believe that these favourable results could be achieved by an extensive confluent laser photocoagulation. But this could only be proved in a carefully monitored trial.
